Table Graph
      published meta-analysis   sensitivity analysis   studies

hydroxychloroquine in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsGalan, 2021 (REV) 1.06 [0.58; 1.95] HAHPS, 2020 7.00 [0.80; 60.90] 2.03[0.35; 11.68]Galan, 2021 (REV), HAHPS, 2020263%253moderatenot evaluable deaths (time to event analysis only)detailed resultsGalan, 2021 (REV) 1.06 [0.58; 1.95] 1.06[0.58; 1.95]Galan, 2021 (REV)10%168NAnot evaluable clinical deteriorationdetailed resultsHAHPS, 2020 1.07 [0.63; 1.82] 1.07[0.63; 1.82]HAHPS, 202010%NAnot evaluable hospital dischargedetailed resultsHAHPS, 2020 0.91 [0.54; 1.54] 0.91[0.54; 1.54]HAHPS, 202010%85NAnot evaluable mechanical ventilationdetailed resultsGalan, 2021 (REV) 7.21 [1.40; 37.04] 7.21[1.40; 37.04]Galan, 2021 (REV)10%168NAnot evaluable ICU admissiondetailed resultsGalan, 2021 (REV) 0.70 [0.33; 1.48] 0.70[0.33; 1.48]Galan, 2021 (REV)10%168NAnot evaluable0.510.01.0relative treatment effectwww.metaEvidence.org2024-04-25 12:33 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 657,832 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons